Key points are not available for this paper at this time.
The global CDR plus NACC FTLD score could be an attractive outcome measure for clinical trials in symptomatic FTLD, and may be useful in natural history studies and clinical trials in FTLD spectrum disorders.
Miyagawa et al. (Wed,) studied this question.